Dr. Amrik Basran
CSO
Amrik brings over two decades of experience in biologic drug discovery and development, spanning early-stage research to clinical application. As CSO, he will lead the translation of ExEd’s intronization technology into a pipeline of innovative therapeutics, starting with recombinant protein therapeutics.
Bio
Amrik completed his PhD at the University of Leicester before working for several years at the Institute of Biotechnology, University of Cambridge. He has a proven track record of building multidisciplinary teams, developing early-stage technology platforms from the bench to the clinic and building collaborations with biotech and pharma companies in the US, Europe and Asia. His expertise spans antibodies, antibody mimetics, targeted radiopharmaceuticals, with experience in half-life extension strategies and novel drug delivery approaches across oncology and inflammatory diseases.
Earlier in his career, Amrik held senior scientific roles at Domantis and GSK and more recently served as CSO at Curadh MTR, CDO at Turbine.AI and was the founder and CSO of the therapeutics division in Cambridge at Avacta Life Sciences.
Amrik brings over two decades of experience in biologic drug discovery and development, spanning early-stage research to clinical application. As CSO, he will lead the translation of ExEd’s intronization technology into a pipeline of innovative therapeutics, starting with recombinant protein therapeutics.
Bio
Amrik completed his PhD at the University of Leicester before working for several years at the Institute of Biotechnology, University of Cambridge. He has a proven track record of building multidisciplinary teams, developing early-stage technology platforms from the bench to the clinic and building collaborations with biotech and pharma companies in the US, Europe and Asia. His expertise spans antibodies, antibody mimetics, targeted radiopharmaceuticals, with experience in half-life extension strategies and novel drug delivery approaches across oncology and inflammatory diseases.
Earlier in his career, Amrik held senior scientific roles at Domantis and GSK and more recently served as CSO at Curadh MTR, CDO at Turbine.AI and was the founder and CSO of the therapeutics division in Cambridge at Avacta Life Sciences.
Amrik brings over two decades of experience in biologic drug discovery and development, spanning early-stage research to clinical application. As CSO, he will lead the translation of ExEd’s intronization technology into a pipeline of innovative therapeutics, starting with recombinant protein therapeutics.
Bio
Amrik completed his PhD at the University of Leicester before working for several years at the Institute of Biotechnology, University of Cambridge. He has a proven track record of building multidisciplinary teams, developing early-stage technology platforms from the bench to the clinic and building collaborations with biotech and pharma companies in the US, Europe and Asia. His expertise spans antibodies, antibody mimetics, targeted radiopharmaceuticals, with experience in half-life extension strategies and novel drug delivery approaches across oncology and inflammatory diseases.
Earlier in his career, Amrik held senior scientific roles at Domantis and GSK and more recently served as CSO at Curadh MTR, CDO at Turbine.AI and was the founder and CSO of the therapeutics division in Cambridge at Avacta Life Sciences.
→